A Phase II Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone Sensitive Prostate Cancer: A-DREAM
Protocol: A032101 SCHEMA A032101 Please Note: Below is partial eligibility, for full eligibility requirements, please contact Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Histologic or clinical diagnosis of metastatic prostate cancer. Must have had evidence of metastatic disease by bone scan, or nodal or visceral lesions on CT […]